Indication and clinical use:
FLUAD^® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and B contained in the vaccine in adults 65 years of age and older.

Contraindications:

• Individuals with a known hypersensitivity to the active substances, to any of the excipients and to eggs, chicken proteins, kanamycin and neomycin sulphate, hydrocortisone, formaldehyde, and cetyltrimethylammonium bromide (CTAB), or in anyone who has had a life-threatening reaction to previous influenza vaccination

Relevant warnings and precautions:

• Do not administer by any other route than intramuscularly
• Patients with endogenous or iatrogenic immunosuppression
• Patients who have had Guillain-Barré syndrome within 6 weeks of receipt of prior influenza vaccine
• Availability of appropriate medical treatment and supervision in case of an anaphylactic event following administration of the vaccine
• Patients with febrile illness or acute infections
• Patients with bleeding disorders
• Monitoring and laboratory tests
• False positive results in serology tests
• Skin

For more information:
Please consult the Product Monograph at https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2020-fluad-product-monograph.pdf for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling us at 1-855-358-8966.